Study Shows Promising Safety, Patient Outcomes Data for MRI-Guided Adaptive Radiation Therapy to Treat Pancreatic Cancer

Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table Adaptive Radiation Therapy, also known as SMART.

Pancreatic Cysts, Cancer and Awareness: Answers from an Expert

Russell Langan, MD, surgical oncologist at Rutgers Cancer Institute of New Jersey, chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center (SBMC) and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, shares more information on monitoring pancreatic cysts and pancreatic cancer.

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.